HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Angiographic perfusion score in patients treated with PCI at late angiography following fibrinolytic administration for ST-segment elevation myocardial infarction is associated with morbidity and mortality at 30 days.

AbstractBACKGROUND:
Among patients with ST-segment elevation myocardial infarction (STEMI), evidence of restoration of both normal epicardial arterial flow and myocardial perfusion early after the administration of fibrinolytic agents has been associated with improved clinical outcomes. In STEMI patients treated with fibrinolytic therapy and scheduled for angiography later during hospital admission, however, the association of later indices of flow and perfusion with clinical outcomes has not been assessed.
METHODS:
Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 enrolled 3,491 STEMI patients treated with fibrinolytic therapy. Angiography was scheduled 48-192 h (median 84) after randomization. The Angiographic Perfusion Score (APS) (the sum of the TIMI Flow Grade and Myocardial Perfusion Grade before and after percutaneous coronary intervention (PCI), range of 0-12) was assessed in the 1,460 patients treated with PCI at late angiography, and its association with morbidity and mortality at 30 days was examined.
RESULTS:
Full perfusion, defined as an APS of 10-12, was associated with the lowest mortality (0.8%), while partial perfusion (APS 4-9) (2.3%) and failed perfusion (APS 0-3) (18.0%) were associated with a higher incidence of mortality at 30 days (P < 0.001 for full perfusion vs. partial perfusion, P < 0.0001 for overall trend). In addition, full perfusion was associated with a lower incidence of recurrent myocardial infarction (MI), a composite of death and MI, recurrent myocardial ischemia, ventricular tachyarrhythmia, congestive heart failure and shock (P < 0.05 for all trends).
CONCLUSION:
Among STEMI patients treated with late PCI following fibrinolytic therapy, higher APS is associated with reduced morbidity and mortality.
AuthorsYuri B Pride, Jacqueline L Buros, Erin Lord, Matthew C Southard, Caitlin J Harrigan, Lauren N Ciaglo, Marc S Sabatine, Christopher P Cannon, C Michael Gibson, TIMI Study Group
JournalJournal of thrombosis and thrombolysis (J Thromb Thrombolysis) Vol. 26 Issue 2 Pg. 106-12 (Oct 2008) ISSN: 0929-5305 [Print] Netherlands
PMID17624497 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Fibrinolytic Agents
  • Platelet Aggregation Inhibitors
Topics
  • Aged
  • Angioplasty, Balloon, Coronary (adverse effects, mortality)
  • Cardiovascular Diseases (etiology, mortality)
  • Coronary Angiography
  • Coronary Circulation
  • Female
  • Fibrinolytic Agents (administration & dosage)
  • Hospital Mortality
  • Humans
  • Male
  • Middle Aged
  • Myocardial Infarction (diagnostic imaging, mortality, physiopathology, therapy)
  • Platelet Aggregation Inhibitors (therapeutic use)
  • Recurrence
  • Retrospective Studies
  • Thrombolytic Therapy
  • Time Factors
  • Treatment Failure

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: